Ryvu advances romaciclib program as FDA clears AML trial expansion
The regulatory decision follows promising results from RIVER-81
The regulatory decision follows promising results from RIVER-81
Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.
Approval is based on results from the phase 3 OASIS 4 clinical trial
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
KIHT can now conduct clinical research for drugs and medical devices, strengthening evidence generation and healthcare innovation
Recognition highlights the hospital network’s decade-long investment in analytics and AI-driven healthcare, supporting improved outcomes, efficiency, and affordability.
The film tells the story of a 70-year-old woman from Kota, Rajasthan, whose persistent cough led to a diagnosis of advanced lung cancer
Company experts to participate in eight sessions covering AI-powered clinical development, regulatory innovation, oncology research, and patient engagement
The milestone, announced from Wilmington, Delaware, is powered through additional Renewable Energy Certificates (RECs) and backed by US-sourced renewable generation
Subscribe To Our Newsletter & Stay Updated